Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC

Jacob Thomas • 31 May 2026
ASCO 2026
Head and Neck Cancer Antibodies Cetuximab Checkpoint Inhibitors FID-007

Jacob Thomas, MD, of the University of Southern California, discusses findings from a Phase II trial (NCT06332092) evaluating FID-007, a novel nanoparticle paclitaxel formulation, in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following checkpoint inhibitor therapy. Dr Thomas highlights promising response rates and durable complete responses observed in this early study. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jacob Thomas

Phase II study of ipatasertib plus pembrolizumab for first-line treatment of R/M HNSCC
1:10
Phase II study of ipatasertib plus pembrolizumab for first-line treatment of R/M HNSCC
Jacob Thomas • 31 May 2026

Related Videos

TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
2:24
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
Ari Rosenberg • 31 May 2026
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
3:02
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
Nabil Saba • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals